Loading…
Loading…
Announcements from Anixa Biosciences, published the moment they cross the wire. Get them by email.
2023
Jul 27, 2023
8:30 AM EDT
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel ovarian cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.
Jul 11, 2023
8:30 AM EDT
The Canadian Intellectual Property Office has issued Canadian Patent 2,989,807 covering Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.
May 22, 2023
8:30 AM EDT
That, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the second patient in the ongoing clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Apr 17, 2023
3:27 PM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer today announced that a technical error was made by the company's website hosting service provider, causing a poster presentation unrelated to Anixa to be posted on the Corporate Presentations page of the…
Apr 17, 2023
1:35 PM EDT
Anixa Biosciences, Inc. (NASDAQ: ANIX ), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the Phase 1 Trial of its breast cancer vaccine.
Mar 27, 2023
8:30 AM EDT
A presentation on results of its Phase 1a breast cancer vaccine trial on April 17, 2023 , at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
Mar 13, 2023
8:30 AM EDT
Its shareholders and the investment community that it does not have any accounts at recently collapsed Silicon Valley Bank.
Mar 02, 2023
8:30 AM EST
Its CEO, Dr. Amit Kumar , will provide a corporate presentation on the company, its business model, and updates on each of its programs and will host a question and answer period after Anixa's 2023 Annual Meeting of Stockholders, being held at 10:00AM PST on March 9, 2023 in a virtual format.
Feb 27, 2023
8:30 AM EST
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology. This technology was invented and developed at Cleveland Clinic and Anixa is the exclusive worldwide licensee.
Feb 21, 2023
8:30 AM EST
The formation of its Breast Cancer Clinical Advisory Board comprising preeminent experts across the breast cancer research and clinical development fields. This represents another milestone as the Company prepares for the next steps in advancing its breast cancer vaccine.
2022
Dec 19, 2022
8:30 AM EST
It will present at the Biotech Showcase 2023 conference being held in-person on January 9-11, 2023 , at the Hilton San Francisco Union Square in San Francisco, California , and virtually on January 18-19 , 2023.
Dec 08, 2022
8:30 AM EST
The maximum tolerated dose (MTD) has been reached in the Phase 1a trial of its preventative breast cancer vaccine.
Nov 08, 2022
8:30 AM EST
A presentation outlining the design of its ongoing breast cancer vaccine trial on December 7, 2022 , at the 2022 San Antonio Breast Cancer Symposium.
Oct 26, 2022
8:30 AM EDT
The initiation of a Phase 1b trial for its preventative breast cancer vaccine. The study is being conducted at Cleveland Clinic and will evaluate safety and monitor immune response.
Oct 10, 2022
8:30 AM EDT
A presentation outlining its ovarian cancer CAR-T therapy trial at the Society for Immunotherapy of Cancer (SITC) 37 th Annual Meeting being held November 8-12 , 2022.
Sep 12, 2022
8:30 AM EDT
The inventor of its ovarian cancer CAR-T technology, Dr. Jose Conejo-Garcia , Senior Member of the Immunology Department at Moffitt Cancer Center, will be speaking at the Rivkin Center and American Association for Cancer Research (AACR) 14 th Biennial Ovarian Cancer Research Symposium.
Aug 31, 2022
8:30 AM EDT
It will present a company update at the H.C. Wainwright 24 th Annual Global Investment Conference being held September 12-14, 2022 (Hybrid Conference).
Aug 15, 2022
8:30 AM EDT
That, in conjunction with its partner Moffitt Cancer Center, it has commenced treatment of the first patient in the clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer.
Jul 21, 2022
8:30 AM EDT
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel breast cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic.
Jun 21, 2022
8:30 AM EDT
The publication of a peer-reviewed journal article in Clinical and Experimental Vaccine Research. The article is titled, "Formulation of an ovarian cancer vaccine with the squalene-based AddaVax adjuvant inhibits the growth of murine epithelial ovarian carcinomas." This paper authored by Suparna Mazumder , Ph.D.,…
